Unlock stock picks and a broker-level newsfeed that powers Wall Street.

High Growth Tech Stocks In The US To Watch April 2025

In This Article:

As the U.S. stock market rebounds from recent declines, with the Dow Jones surging over 1,000 points and tech-heavy indices like the Nasdaq Composite seeing significant gains, investors are closely monitoring high-growth tech stocks amid ongoing economic uncertainties such as tariff impacts and Federal Reserve dynamics. In this environment, identifying promising tech companies involves assessing their resilience to market volatility and their ability to capitalize on technological advancements while navigating broader economic challenges.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.29%

29.79%

★★★★★★

TG Therapeutics

26.03%

37.60%

★★★★★★

Travere Therapeutics

28.65%

66.06%

★★★★★★

Arcutis Biotherapeutics

25.76%

58.17%

★★★★★★

Alkami Technology

20.46%

85.16%

★★★★★★

Alnylam Pharmaceuticals

22.96%

58.81%

★★★★★★

TKO Group Holdings

22.27%

25.17%

★★★★★★

AVITA Medical

27.81%

55.17%

★★★★★★

Lumentum Holdings

21.35%

120.49%

★★★★★★

Ascendis Pharma

32.84%

59.74%

★★★★★★

Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

XOMA Royalty

Simply Wall St Growth Rating: ★★★★★☆

Overview: XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific, with a market cap of $253.71 million.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $28.49 million. Its business model focuses on aggregating biotech royalties across the United States and the Asia Pacific regions.

Despite XOMA Royalty's current unprofitability, its projected path to profitability within three years aligns with an above-market expected annual profit growth. This trajectory is complemented by a robust revenue increase of 28.4% per year, significantly outpacing the US market average of 8.2%. Recent engagements, such as their presentation at the Jones Healthcare and Technology Innovation Conference, underscore their active role in sector dialogues, potentially enhancing investor confidence. Moreover, the company's strategic dividend announcements for preferred stockholders suggest a commitment to returning value while navigating towards profitability. These elements collectively highlight XOMA's potential in transitioning from a high-growth phase to achieving sustainable financial metrics.

NasdaqGM:XOMA Earnings and Revenue Growth as at Apr 2025
NasdaqGM:XOMA Earnings and Revenue Growth as at Apr 2025

Xerox Holdings

Simply Wall St Growth Rating: ★★★★☆☆